We investigated the genetic overlap between Alzheimer's disease (AD) and Parkinson's disease (PD). Using summary statistics (P-values) from large recent genome-wide association studies (GWAS) (total n = 89 904 individuals), we sought to identify single nucleotide polymorphisms (SNPs) associating with both AD and PD. We found and replicated association of both AD and PD with the A allele of rs393152 within the extended MAPT region on chromosome 17 (meta analysis P-value across five independent AD cohorts = 1.65 × 10 − 7 ). In independent datasets, we found a dose-dependent effect of the A allele of rs393152 on intra-cerebral MAPT transcript levels and volume loss within the entorhinal cortex and hippocampus. Our findings identify the tau-associated MAPT locus as a site of genetic overlap between AD and PD, and extending prior work, we show that the MAPT region increases risk of Alzheimer's neurodegeneration. or o.a.andreassen@medisin.uio.no 38 Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://www.loni.usc.edu/ADNI/Data/ADNI_Authorship_List.pdf. 39 Full list of investigators included in the Supplemental materials.
INTRODUCTION
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative disorders. Neuropathologically, AD is characterized by the presence of extracellular amyloid-β plaques and intracellular tau-associated neurofibrillary tangles, whereas PD involves deposition of α-synuclein-containing Lewy bodies. 1 Though AD and PD are considered distinct neurodegenerative entities, there is evidence for Lewy body pathology in AD 2 and Alzheimer's-type pathology in PD 3 suggesting overlap between these two disorders. Importantly, although tau-associated pathology is considered a hallmark of AD, genome-wide association studies (GWAS) in PD have identified several polymorphisms in and around the tau-encoding microtubule-associated protein gene (MAPT) 4, 5 indicating that similar biochemical perturbations may contribute to both AD and PD. 6 Furthermore, prior reports investigating the genetic relationship between MAPT and AD risk have been conflicting, with some studies finding a positive association 7, 8 and other studies showing no association, 8, 9 indicating that the role of the MAPT gene in influencing Alzheimer's neurodegeneration is still largely unknown.
Combining GWAS from two disorders provides insights into genetic pleiotropy (defined as a single gene or variant being associated with more than one distinct phenotype) and could elucidate shared pathobiology. Here, using summary statistics (P-values) from large genetic studies, [10] [11] [12] [13] [14] we sought single nucleotide polymorphisms (SNPs) associating with both AD and PD.
METHODS

Participant samples
We obtained complete GWAS results in the form of summary statistics from the PD International Parkinson's Disease Genetics Consortium (IPDGC) and AD Alzheimer's Disease Genetics Consortium (ADGC). The PD GWAS summary statistic results from IPDGC consisted of 5333 cases and 12 019 controls obtained from five studies with genotyped and imputed data at 7 689 524 SNPs (Table 1a , for additional details, see International Parkinson Disease Genomics Consortium 10 ). The AD GWAS summary statistic data from ADGC consisted of 11 840 cases and 10 931 controls obtained from 15 studies with genotyped and imputed data at 2 324 889 SNPs (Table 1a , for additional details, see Naj et al. 11 ). The ADGC GWAS summary statistic data were co-varied for age, sex and number of apolipoprotein E (APOE) alleles. There was no overlap between the ADGC and the IPDGC cases/controls.
To test for replication, we also assessed the P-values of the PD genomewide significant SNPs in four separate AD cohorts, namely the Genetic and Environmental Risk in Alzheimer's Disease (GERAD) sample, a cohort of AD cases and controls drawn from the population of Iceland (deCODE cohort), a small cohort of mild cognitive impairment or AD cases and controls drawn from the population of Norway (Oslo), and the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. The AD GWAS summary statistic results from the GERAD consortium were obtained from 13 studies and consisted of 3941 cases (62.7% female) and 7848 controls (55.6% female) with genotyped data at 529 205 SNPs (for additional details, see Harold et al. 12 ). A total of 5571 controls from the PD IPDGC GWA were also present in the AD GERAD GWA. The AD GWAS summary statistic data drawn from the Icelandic population (deCODE) included 3759 AD cases (65.8% female) and 8888 older controls (57.8% females) greater than 85 years of age (for additional details, see Jonsson et al. 13, 14 ). The AD GWAS summary statistic data from the CHARGE consortium were obtained from four studies and included 1315 AD cases (62.1% female) and 21 766 controls (56.9% female) (for additional details, see Lambert et al. 15 ). The AD GWAS summary statistic data drawn from the Norwegian population (Oslo) included 434 individuals classified as AD or mild cognitive impairment (57% female) and 1830 controls (49% female) (for additional details, please see Supplementary Information).
These studies addressed potential concerns of population stratification by limiting analysis to individuals of European descent, including principal components of genetic variation in the regression tests and controlling post hoc for genomic inflation with genomic control (for additional details, see International Parkinson Disease Genomics Consortium, 10 Naj et al., 11 Harold et al., 12 Jonsson et al. 13, 14 and Lambert et al. 15 ).
For the gene expression analyses, we used publicly available, genotyping (performed on the Affymetrix GeneChip Human Mapping 500K Array Set platform (Santa Clara, CA, USA)) and RNA expression data (performed on the Illumina HumanRefseq-8 Expression BeadChip system (San Diego, CA, USA)) from neuropathologically confirmed 176 late-onset AD cases (mean age = 83.4 years, s.d. = 6.6) and 188 controls (mean age = 81.2 years, s.d. = 9.1) from the Gene Expression Omnibus (GEO) data set GSE15222. 16 We additionally evaluated genotype and imaging data obtained from 620 older participants (174 healthy older controls, 311 individuals with mild cognitive impairment and 135 individuals with probable AD) from the Alzheimer's Disease Neuroimaging Initiative (ADNI -see Table 1b and Supplementary Methods). We restricted our analyses to those participants with available genotype and quality-assured baseline and follow-up MRI scans (6 months to 3.5 years, mean of 2.02 years, s.d. = 0.80 years) available as of April 2011. We assessed longitudinal sub-regional change in grey matter volume (atrophy) on serial 2471 T 1weighted MRI scans using a modified version of the FreeSurfer software package (for additional details, see Supplementary Methods).
Statistical analyses
We used stepwise gatekeeper hypothesis testing 17 to identify SNPs associating with both PD and AD. We restricted our analyses to only those SNPs assayed in both GWASs from the IPDGC and the ADGC Consortia. First, we identified 'pruned' SNPs (removing all SNPs with r 2 40.2, within 1 Mb of a given SNP) that were significant at a genome-wide level (Po 5 × 10 − 8 ) within PD. Next, we evaluated the P-values of these PD genome-wide significant SNPs within the AD ADGC GWAS APOE, age and sex co-varied summary statistic P-values) and applied a Bonferroni correction to control for multiple comparisons. Note that because the SNPs were a priori selected independently of the P-values from AD ADGC, the proper Bonferroni correction is in terms of the number of PD genomewide significant SNPs. Therefore, the P-value threshold for detecting significant ADGC loci controls for the number of PD genome-wide significant SNPs rather than P o5 × 10 − 8 . It is important to note that this stepwise gatekeeper hypothesis testing approach implies a strict control for family-wise error rate in a multiple testing framework. 17 
RESULTS
Genetic overlap between AD and PD at the A allele of rs393152
We found eight SNPs on four chromosomes that were genomewide significant in PD, thus requiring a Bonferroni-corrected P-value significance threshold of 0.00625 ( Table 2 ). Across all eight SNPs, we found that the A allele of rs393152, within the CRHR1 region on chromosome 17 (within the extended MAPT locus) and with a minor allele frequency of 23.1%, significantly increased AD risk in the ADGC cohort (P-value = 1.17 × 10 − 4 , odds ratio (OR) for the minor allele = 0.90, 95% confidence interval (CI) = 0.86-0.95) ( Table 2 ; Figure 1 ). In a replication analysis, we found that the A allele of rs393152 also significantly increased AD risk within the GERAD (one-tailed P-value = 0.0048, OR for the minor allele = 0.92, 95% CI = 0.86-0.98), deCODE (one-tailed P-value = 0.017, OR for the minor allele = 0.92, 95% CI = 0.85-0.99) and Oslo cohorts (one-tailed P-value = 0.047, OR for the minor allele = 0.85, 95% CI = 0.71-1.02). We replicated the directionality of effect for the A allele of rs393152 within the CHARGE cohort (one-tailed P-value = 0.318, OR for the minor allele = 0.97, 95% CI = 0.85-1.10). We conducted an inverse variance-weighted meta-analysis 18 and found a two-tailed meta-analysis P-value of 1.65 × 10 − 7 (meta analysis OR = 0.91, 95% CI = 0.88-0.94) ( Figure 1 ). We evaluated the statistical power for detecting an association of rs393152 with AD across the discovery (ADGC) and the combined, meta-analysis AD cohorts (ADGC+GERAD+deCODE +Oslo+CHARGE). Using a GWAS threshold of P o5 × 10 − 8 , the power within ADGC was 0.028 and within the meta-analysis cohort was 0.36, demonstrating that even the combined cohort consisting of 21 289 AD cases and 51 263 controls was underpowered to detect an association between AD and rs393152 using a standard GWAS approach. However, leveraging PD such that power is computed conditional on discovery in the PD sample (stepwise gatekeeper hypothesis testing), by using P o 0.00625 (where Bonferroni corrected P = 0.05/number of genome-wide significant SNPs in PD), the power within ADGC was 0.854 and within the meta-analysis cohort was 0.998 indicating that restricting evaluation to only PD-significant SNPs results in considerable increase in statistical power for AD gene discovery. We also calculated the sample size needed to detect rs393152
, where Θ -1 is the inverse standard normal cumulative distribution function) and found that in comparison with our discovery cohort, 4.5 times as many subjects would be needed to detect rs393152 using a standard GWAS approach at the same alpha/Type I error.
On the basis of the 1000 Genomes Project LD structure, we found that rs393152 was in r 2 LD40.8 with a number of variants within the MAPT gene on chromosome 17 (Figure 2a ). Fine mapping showed that rs1981997 constituted the peak of the AD association signal within MAPT (r 2 = 1.0 with rs393152 in HapMap 2; Figure 2b ). Across the ADGC (risk allele = A, two-tailed P-value = 9.54 × 10 − 5 , OR = 0.90, 95% CI = 0.85-0.95), GERAD (one-tailed P-value = 0.006, OR = 0.92, 95% CI = 0.86-0.98, deCODE (one-tailed P-value = 0.018, OR = 0.92, 95% CI = 0.84-0.99), Oslo (one-tailed P-value = 0.047, OR = 0.85, 95% CI = 0.71-1.03) and CHARGE (one-tailed P-value = 0.0327, OR = 0.96, 95% CI = 0.84-1.08) cohorts, the leading SNP in the MAPT region, rs1981997, demonstrated a similar meta-analysis P-value to rs393152 (twotailed meta-analysis P-value of 1.29 × 10 − 7 , see Supplementary Figure 4 ) providing further evidence that our AD/PD pleiotropic variant was tagging the MAPT gene and not a false-positive result. We also note that rs393152 has been previously shown to tag the H1 haplotype at the MAPT locus (r 2 = 0.761). 5 Because of the extensive LD structure in this region, we cannot exclude the possibility that other genes, besides MAPT, are the pathologically relevant genes. However, MAPT is biologically the most plausible candidate.
Non-polygenic pleiotropy between AD and PD We further investigated whether the observed genetic overlap between AD and PD was polygenic and generalizable across a number of loci or non-polygenic and driven by the MAPT locus alone. Using recently developed statistical methods to evaluate pleiotropic effects, [19] [20] [21] [22] we investigated relative 'enrichment' of pleiotropic SNPs in AD (APOE, age and sex co-varied summary statistic P-values from ADGC) as a function of significance in PD (summary statistic P-values from IPDGC) (for additional details, see Supplementary Methods). Removing the MAPT-associated genetic signal, consisting of all SNPs in r 2 40.2 (based on 1000 Genomes Project LD structure) within 1 Mb of MAPT variants, resulted in considerable attenuation of genetic enrichment ( Supplementary  Figures 1a and d) indicating that the observed pleiotropy between AD and PD was non-polygenic and likely confined to the MAPT region. Similarly, after 'pruning' (removing SNPs in r 2 40.2) all available ADGC SNPs, we found a single pleiotropic locus on chromosome 17 between AD and PD that was in r 2 = 1.0 with Genetic overlap between AD and PD MAPT. Though some genetic enrichment was still present after removing the MAPT-associated SNPs, we found a similar pattern in PD SNP enrichment conditioned on AD ( Supplementary  Figure 2 ).
AD-PD pleiotropic locus correlates with MAPT transcript levels
We assessed the relationship between the AD-PD pleiotropic locus on chromosome 17 and MAPT transcript levels within the brain (target id = GI_8400714-A and reference sequence = NM_016841. 1 in GSE15222, for additional details, see Webster et al. 16 and Myers et al. 23 ). As rs393152 was not available in the GEO dataset, we focused on rs422112 within the CRHR1 locus on chromosome 17, the best available proxy (closest distance and r 2 40.98) for rs393152. We used an additive model with minor allele (T) counts coded as 0, 1 and 2. Given the allele frequencies and nearcomplete LD between rs393152 and rs422112, the 'A' allele of rs393152 tags the 'C' allele of rs422112 and the 'G' allele of rs393152 tags the 'T' allele of rs422112. Using linear regression, covarying for the effects of age at death, APOE ε4 carrier status, diagnosis (AD cases vs controls), brain tissue region (frontal, parietal, temporal or cerebellar), postmortem interval, institute source of sample and hybridization date, we evaluated the relationship between rs422112 and MAPT transcript expression levels. Across all cases and controls, we found a strong association between the T allele of rs422112 and decreased MAPT transcript expression levels (standardized β-coefficient = − 0.27, t-statistic = − 6.61, P-value = 1.45 × 10 −10 ), which corresponds to presence of the A allele of rs393152 and increased MAPT transcript expression ( Figure 3 ). Subgroup analyses demonstrated similar results within the AD cases and controls (see Supplementary Results) . We further assessed the specificity of our findings by evaluating the relationship between the AD-PD pleiotropic locus and transcript levels of synaptophysin (SYP), a neuronal protein, and synuclein (SNCA), a neural protein associated with tau and PD. In contrast to MAPT transcript levels, we found no relationship between rs422112 and transcript levels of either SYP or SNCA (see Supplementary Results and Figure 3 ). We additionally performed a 'locus-wide association study' testing all SNPs in the MAPT region for association with MAPT transcript expression levels. SNPs in r 2 = 1.0 with rs393152 constituted the peak of the association signal (Po 1.0 × 10 − 8 ) with MAPT transcript expression levels ( Figure 4 ). We also evaluated the relationship between SNPs in LD with rs393152 and transcript levels of other chromosome 17 genes within the larger MAPT region that were available within GSE15222. 16 As illustrated in Supplementary Figures 3a and f , SNPs in LD with rs393152 did not demonstrate significant association with transcript levels of other genes within the MAPT region further illustrating the specificity of our MAPT findings.
AD-PD pleiotropic locus correlates with longitudinal brain atrophy
Using linear mixed effects models, we assessed the relationship of rs393152 with longitudinal brain atrophy specifically within the entorhinal cortex and hippocampus, two medial temporal lobe regions selectively affected in the earliest stages of AD. 24 These models co-varied for the effects of baseline age, sex, education, group status (healthy older control vs mild cognitive impairment vs AD), disease severity (Clinical Dementia Rating-Sum of Box score) and APOE ε4 carrier status. We used an additive model with major allele (A) counts coded as 0, 1, and 2. Across all available ADNI participants, we found that the A allele of rs393152 was significantly associated with increased atrophy rates (volume loss) of the entorhinal cortex (standardized β-coefficient = − 0.003, s.e. = 0.001, P-value = 0.0071) and hippocampus (standardized βcoefficient = − 0.003, s.e. = 0.001, P-value = 0.0031).
AD-PD pleiotropic locus demonstrates larger effect among APOE ε4 non-carriers
We further assessed the relationship between rs393152, MAPT transcript expression levels and medial temporal lobe atrophy separately among APOE ε4 carriers (presence of at least one ε4 allele) and non-carriers (absence of at least one ε4 allele). Using the linear regression and mixed effects model framework described above, we found a stronger effect between rs393152 and MAPT transcript expression levels among APOE ε4 non-carriers (standardized β-coefficient = − 0.22, s.e. = 0.04, P-value = 1.1 × 10 − 6 ) than the APOE ε4 carriers (standardized β-coefficient = − 0.14, s.e. = 0.04, P-value = 0.001). Similarly, we found a stronger effect between rs393152 and medial temporal lobe atrophy among APOE ε4 noncarriers (entorhinal cortex: standardized β-coefficient = − 0.002, s.e. = 0.001, P-value = 0.04; hippocampus: standardized β-coefficient = − 0.003, s.e. = 0.001, P-value = 0.01) than among APOE ε4 carriers (entorhinal cortex: standardized β-coefficient = − 0.003, s.e. = 0.002, P-value = 0.07; hippocampus: standardized β-coefficient = − 0.003, s.e. = 0.002, P-value = 0.07) ( Figure 5 ).
DISCUSSION
In this study, we leveraged gene variants associating with PD to search for variants that associate with AD. We found a gene variant that was in strong LD with markers in the MAPT gene on chromosome 17 and that was previously associated with PD. This SNP was significantly associated with longitudinal atrophy of the entorhinal cortex and hippocampus and demonstrated a strong association with MAPT transcript levels within the brain.
Considered together, our findings point to the tau-associated MAPT locus as a site genetic overlap between AD and PD.
These results indicate that leveraging the genetic signal in one phenotype may improve statistical power for gene discovery in a second, related phenotype. Rather than evaluating all possible AD susceptibility loci, we restricted our analyses to only those eight SNPs that were below genome-wide threshold in PD. As such, detection of AD susceptibility loci only among genome-wide significant PD susceptibility loci obviates the need for applying a Po 5 × 10 −8 threshold and constitutes stepwise gatekeeper hypothesis testing. 17 This two-stage stepwise gatekeeper framework is conceptually similar to the 'proxy-phenotype' method, which has recently been utilized to identify common variants associated with cognitive performance. 25 It is important to note that this approach does not lower the statistical 'bar' for gene discovery and maintains a constant Type I error rate. By exploiting the statistical power from PD, we were able to identify one SNP within the CRHR1 locus on chromosome 17 (meta-analysis P-value = 1.65 × 10 − 7 , OR = 0.91, 95% CI = 0.88-0.94) that was significantly associated with increased AD risk. Importantly, the use of this stepwise, pleiotropic approach, where power is computed conditional on discovery in the PD sample, resulted in considerable improvement in statistical power for AD gene detection. In contrast, using a standard GWAS approach, neither the discovery ADGC cohort nor the combined meta-analysis cohort were sufficiently powered to detect rs393152. Given the comparable sample sizes with our current study, it is likely that the original AD GWASs 11, 12, 26, 27 and even the recent meta-analysis (stage 1) 15 were underpowered to detect MAPT-associated signal in AD.
There are several indications that the detected pleiotropy within chromosome 17 represents biological signal and not analysis artifacts or type 1 error. First, the use of APOE co-varied SNPs from the ADGC minimizes concerns that the detected SNPs represent spurious association resulting from the known large effect of APOE on AD risk (for an example of this, see Wijsman et al. 28 ). Importantly, our findings indicate the presence of genetic signal independent of the chromosome 19 APOE cluster. Second, rs393152 was significantly associated with AD risk in three independent AD replication cohorts and demonstrated equivalent effect sizes in all five AD cohorts. Third, the identified pleiotropic locus was in r 2 LD40.8 with a number of variants within the tau-encoding MAPT gene on 17q21 indicating that the detected signal was specific to the MAPT region. Fourth, the leading AD-associated SNP in the MAPT region (rs1981997, r 2 LD = 1.0 with rs393152 in the HapMap 2) demonstrated a similar meta-analysis P-value to rs393152 providing further evidence that our AD/PD pleotropic SNP was not a false-positive result. Finally, the A allele of rs393152 showed a dose-dependent effect specifically with MAPT transcript levels within the brain and was significantly associated with longitudinal medial temporal lobe atrophy, an established endophenotype of Alzheimer's neurodegeneration.
These single locus results point to shared pathobiology between AD and PD. Although we cannot exclude the possibility that other genes at this chromosome 17 locus are the pathologically relevant genes, our data are biologically plausible and consistent with prior experimental evidence establishing the role of MAPT in neurodegenerative diseases. 28 The pleiotropic variant we found, rs393152, tags the H1 haplotype at the MAPT locus, 5 which has been associated with a number of tauopathies including corticobasal degeneration, progressive supranuclear palsy and PD. 5, 29 Furthermore, broadly consistent with a prior study, 30 our results suggest non-extensive, non-polygenic pleiotropy between AD and PD localized to the MAPT cluster on chromosome 17.
Despite a number of prior studies, [7] [8] [9] 31 the role of MAPT in AD is still unclear. Extending prior work suggesting a significant relationship between the MAPT H1 7 (within the GERAD cohort) and H2 8 (within the ADGC cohort) haplotypes and AD risk, our findings indicate that the A allele of rs393152, which tags the H1 haplotype at the MAPT locus, 5 increases risk for AD. Building on prior research demonstrating a robust association between a variant in the H2 haplotype and reduced MAPT brain expression levels, 8 we found a dose-dependent effect of the A allele of rs393152 ( Figure 3 ) on intracranial MAPT gene expression. In contrast, we found no association between rs393152 and transcript levels of either synaptophysin or synuclein indicating the specificity of the relationship between the identified AD-PD pleiotropic locus and MAPT transcript expression. Our gene expression findings are consistent with prior work demonstrating a significant relationship between the H1 haplotype and MAPT levels. 23, 32 However, a previous study 33 of exon levels from multiple human brain regions found no association between the H1c subhaplotype and MAPT expression indicating that additional work using large samples is needed to systematically investigate the H1/H2 sub-haplotypes and MAPT brain expression levels. Additionally, building on prior work detecting smaller grey matter volumes within cognitively normal 34 and cognitively impaired carriers of the MAPT H1 haplotype, 35 we found a significant relationship between the A allele of rs393152 and longitudinal atrophy of the entorhinal cortex and hippocampus, two medial temporal lobe regions selectively affected with tauassociated neurofibrillary pathology in the earliest stages of AD. Considered together, this suggests that the PD-associated MAPT region influences Alzheimer's neurodegeneration likely via taurelated mechanisms.
From an AD perspective, these results highlight the importance of considering tau. Recent evidence indicates that dominantly inherited mutations in MAPT cause forms of frontotemporal dementia with parkinsonism, 28 a rare MAPT variant (p.A152T) increases risk for AD and frontotemporal dementia syndromes, 36 and tau modulates amyloid-β-associated Alzheimer's neurodegeneration. 37 Consistent with this work, our present results indicate that tau-associated polymorphisms impact MAPT transcript levels and affect medial temporal lobe volume loss. When considered together with prior CSF, [38] [39] [40] and imaging research, 41, 42 our findings suggest that data from GWAS, expression quantitative trait loci and structural imaging measures may better elucidate underlying pathobiology than any of these markers by themselves. These results also demonstrate the utility of using entorhinal cortex and hippocampal atrophy rates as endophenotypes to identify and confirm AD risk variants.
In this study, the diagnosis of AD and PD was based on clinical evaluations, without histopathological confirmation. Postmortem evidence indicates the co-occurrence of α-synuclein, tangle and amyloid pathology. 43 Therefore, one concern is that concomitant Parkinson's pathology may have contributed to our MAPTassociated effect in AD. In a small cohort of autopsy-confirmed AD cases and controls, we replicated the directionality and magnitude of the A allele of rs393152 (Supplementary Figure 5) indicating that our AD-associated findings are not due to concomitant PD pathology. Furthermore, building on prior genetic work, 44 among APOE ε4 non-carriers, we found a stronger relationship between rs393152 and both gene expression levels and medial temporal lobe atrophy ( Figure 5 ) suggesting that MAPT may predominantly influence Alzheimer's neurodegeneration in a smaller subset of individuals who do not possess APOE ε4 alleles. As a caveat, we note that because we primarily evaluated summary statistics from the discovery and replication cohorts, additional work with raw genotype data is needed to determine whether the AD-associated MAPT effect varies based on APOE ε4 carrier status. Another concern is the potential 'contamination' of PD samples with other tauopathies (such as progressive supranuclear palsy and corticobasal degeneration) strongly associated with MAPT. Using neuropathologically confirmed PD cases, a recent study 45 found a significant association between rs393152 and idiopathic PD indicating that our current findings are unlikely due to contamination with unrecognized cases of progressive supranuclear palsy or corticobasal degeneration.
From a translational perspective, this work illustrates that data from large GWAS and a pleiotropic framework can provide important insights into the relationships between various diseases. Complementary to recently developed polygenic pleiotropic methods, [19] [20] [21] [22] the analytic framework used in this manuscript is useful for detecting non-polygenic pleiotropy and can be integrated with other biomarkers to test biologically driven hypotheses. The combination of genetic, molecular and neuroimaging measures may be additionally helpful for detecting and quantifying the biochemical effects of therapeutic interventions.
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